


I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of ~~treating or preventing~~ an angiogenesis-related disorder in a patient suffering from such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:



wherein

R = H, C₁₋₄ (un)branched alkyl, CF₃, SR⁴;

Y = OR', NR''R';

R' = H, C₁₋₁₀ (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

-(CH₂)_nZ(CH₂)_nA;

n = 2-6;

n' = 1-6;

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR³, NR³C(=O), S(O)_n2, CHOR³, NR³;

n² = 0-2;

R³ = H, C₁₋₆ (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below);

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH₂)_nOR³;

R'' = H, OH, OR';

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)_n2R⁴, CF₃, R⁴, NO₂;

R⁴ = C₁₋₆ (un)branched alkyl;

$m = 0-3$;

$m' = 0-5$; and

$W = O, H$.

2. (original) The method of Claim 1 wherein

$R = H, C_{1-2}$ alkyl;

$Y = NR'R''$

$R' = H, C_{1-6}$ (un)branched alkyl, $-(CH_2)_nZ(CH_2)_nA$;

$Z = \text{nothing}, O, CHOR^3, NR^3$;

$R_3 = H$;

$A = H, OH, \text{(un)substituted aryl (substitution as defined by X below)}$;

X and X' independently = $H, F, Cl, Br, CN, CF_3, OR', SR^4, R^4$;

$R'' = H$;

$R^4 = C_{1-4}$ (un)branched alkyl;

$m = 0-2$;

$m' = 0-2$;

$W = H$;

$n = 2-4$; and

$n' = 0-3$.

3. (original) The method of Claim 2 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

4. (original) The method of Claim 1 wherein the angiogenesis-related disorder is an ophthalmic angiogenesis-related disorder.

5. (original) The method of Claim 4 wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.

6. (original) The method of Claim 5 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).

7. (original) The method of Claim 4 wherein the angiogenesis-related disorder is selected from the group consisting of exudative macular degeneration; proliferative diabetic retinopathy; ischemic retinopathy; retinopathy of prematurity; neovascular glaucoma; iritis rubeosis; corneal neovascularization; cyclitis; sickle cell retinopathy; and pterygium.

8. (original) The method of Claim 1 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.

9. (original) The method of Claim 1 wherein the angiogenesis-related disorder is selected from the group consisting of prostate cancer; lung cancer; breast cancer; bladder cancer; renal cancer; colon cancer; gastric cancer; pancreatic cancer; ovarian cancer; melanoma; hepatoma; sarcoma; and lymphoma.